- The FDA is asking states to temporarily halt using J&J’s Covid-19 vaccine after six people in the U.S. developed a rare blood-clotting disorder.
- The FDA said the recommendation is “out of an abundance of caution.”
- The cases occurred in women ages 18 to 48, with symptoms developing six to 13 days after they received the shot.
All six cases occurred in women ages 18 to 48, with symptoms developing six to 13 days after they received the shot. Doctors typically treat that type of blood clot with heparin, but health regulators noted that could be dangerous in this case and recommended a different treatment.
J&J said in a statement that “no clear causal relationship” has been identified between the blood clots and the vaccine, adding it is working closely with regulators to assess the data.
People who receive the vaccine and “develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider,” the FDA and CDC said. Read More